<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532750</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-2016-25151</org_study_id>
    <nct_id>NCT03532750</nct_id>
  </id_info>
  <brief_title>Splenic Embolization for Portal Hypertension</brief_title>
  <official_title>Safety and Efficacy of Splenic Artery Embolization to Treat Symptomatic Portal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and efficacy of partial splenic&#xD;
      artery embolization in the treatment of symptomatic portal vein hypertension. A secondary aim&#xD;
      is to evaluate the relative efficacy of two separate splenic artery embolization techniques,&#xD;
      coiling versus particle embolization of the spleen. These two methods will be compared to&#xD;
      standard medical management which consist of pain management and fluid draining.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center phase I/II study that is designed to assess the safety and efficacy&#xD;
      of splenic artery embolization in the setting of symptomatic portal hypertension. All&#xD;
      participating investigators have signed the protocol agreement and no investigator will be&#xD;
      added until they sign the agreement. The study will not be initiated until FDA and IRB&#xD;
      approval is obtained.&#xD;
&#xD;
      The study will consist of a 4 week screening period, day of treatment, and 12-month follow-up&#xD;
      period. 60 subjects will be enrolled, with a goal of randomizing 30, at the University of&#xD;
      Minnesota Medical Center. Enrollment is expected to take up to 48 months. The collection of&#xD;
      data will be accomplished by utilizing a clinical research team that will obtain symptomatic&#xD;
      portal hypertension improvement and safety assessments. Efficacy assessments will include;&#xD;
      change in portal vein velocity, ascitic fluid production change, reduction in splenic size,&#xD;
      and improvement in quality of life (QoL). Safety assessments include subject and investigator&#xD;
      reported adverse events, subjective pain, and splenic abscess formation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1:1 randomization of participants in sequential order to either the control group (best medical management), particle embolization, and coil embolization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>pre-procedural (baseline) and at 1, 3, 6, and 12 month follow-up visits</time_frame>
    <description>Administration of the Chronic Liver Disease Questionnaire (CLDQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Adverse Events</measure>
    <time_frame>Patients will be evaluated for adverse events post procedural at 72hrs, 1 week, and 1, 3, 6, and 12 months</time_frame>
    <description>Evaluation of all procedure-related adverse events (PRAE) and serious adverse events (SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascites Production</measure>
    <time_frame>pre-procedural and at 1, 3, and 6 months</time_frame>
    <description>Fluid production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Splenic Size</measure>
    <time_frame>pre-procedural and at 1,3,6 and 12 months</time_frame>
    <description>Changes in size of spleen as indicated by MRI or CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal Vein Velocity</measure>
    <time_frame>pre-procedural and at 1, 6 and 12 months</time_frame>
    <description>Changes in flow volume and velocity as evidenced by ultra sound</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Particle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to receive either the Embozene or Embosphere particles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to receive either Ruby or Interlock detachable coils</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Particle</intervention_name>
    <description>300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.&#xD;
300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.&#xD;
Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.&#xD;
Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578.</description>
    <arm_group_label>Particle</arm_group_label>
    <other_name>Embosphere Particles</other_name>
    <other_name>Embozene Particles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coil</intervention_name>
    <description>Ruby or Interlock detachable coils</description>
    <arm_group_label>Coil</arm_group_label>
    <other_name>Ruby Detachable Coils</other_name>
    <other_name>Interlock Detachable Coils</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients who are between 22-70 years of age.&#xD;
&#xD;
               -  Patient must have portal hypertension; as defined by: refractory ascites or&#xD;
                  unilateral right sided pleural effusions with concomitant liver cirrhosis and&#xD;
                  splenomegaly (spleen &gt; 11 cm on CT or US).&#xD;
&#xD;
               -  Medically refractive/intolerant, ascites or unilateral right sided pleural&#xD;
                  effusions consistent with hepatic hydrothorax. Medically refractive defined as&#xD;
                  those with persistent need for paracentesis or thoracentesis despite maximal&#xD;
                  doses of diuretics (400 mg spironolactone and 160 mg furosemide per day) or those&#xD;
                  who are intolerant of furosemide (develop azotemia, electrolyte imbalance,&#xD;
                  encephalopathy or renal failure) or spironolactone (develop gynecomastia,&#xD;
                  decreased libido, and hyperkalemia).&#xD;
&#xD;
               -  Patients will need to meet one or more of the following requirements:&#xD;
&#xD;
                    -  MELD &gt;18 but &lt;35&#xD;
&#xD;
                    -  Anatomic variation making TIPS impossible/difficult&#xD;
&#xD;
                    -  Previous failed attempt to place TIPS&#xD;
&#xD;
                    -  Unwilling to undergo TIPS&#xD;
&#xD;
                    -  History of severe hepatic encephalopathy&#xD;
&#xD;
                    -  Thrombosis of the hepatic veins&#xD;
&#xD;
               -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 22 and &gt;70 years of age&#xD;
&#xD;
          -  Patients with CLDQ score of &gt;6 or &lt;2&#xD;
&#xD;
          -  Patients with a weight &gt;400 pounds&#xD;
&#xD;
          -  Patients with primary or secondary splenic cancer&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Current systemic infection&#xD;
&#xD;
          -  Patients who have undergone prior splenectomy or other splenic surgery&#xD;
&#xD;
          -  Patients who have previously undergone splenic artery embolization for any reason&#xD;
             (likely reasons would be trauma or thrombocytopenia)&#xD;
&#xD;
          -  Patients with splenic vascular anatomy that would increase the risk of non-target&#xD;
             embolization.&#xD;
&#xD;
          -  Patients who have a INR or platelet count which are not correctable to &lt;1.8 and&#xD;
             &gt;35,000 respectively&#xD;
&#xD;
          -  Anaphylaxis to intravenous contrast.&#xD;
&#xD;
          -  Patients diagnosed with Budd-Chiari Syndrome (This will be assessed on&#xD;
             pre-intervention CTA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamar Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shamar Young, MD</last_name>
    <phone>612-626-5388</phone>
    <email>youn1862@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nichole Kent</last_name>
    <phone>612-624-6904</phone>
    <email>simme033@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamar Young, MD</last_name>
      <phone>612-626-5566</phone>
      <email>youn1862@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All IPD generated for this study will only be reviewed by the study personnel who have been approved by the IRB. Any results that are shared, will be aggregate group data that does not address any individual participant directly.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

